Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]Colon Cancer Treatment (PDQ®) NCI. 2014-05-12. Retrieved 29 June (2014)

  • [2]Defining Cancer. National Cancer Institute. Retrieved 10 June (2014)

  • [3]Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64 (1):9-29 (2014)

  • [4]World Cancer Report 2014. World Health Organization. pp. Chapter 1.1. (2014)

  • [5]Hawk ET, Levin B: Colorectal cancer prevention. J ClinOnco l 23 (2):378-91 (2005)

  • [6]Hong L, Han Y, Zhang H, Zhao Q, Yang J, Ahuja N: High expression of epidermal growth factor receptor might predict poor survivalin patients with colon cancer: a meta-analysis. Genet Test Mol Biomarkers 17 (4):348-51 (2013)

  • [7]Gazzaniga P, Nofroni I, Gandini O, Silvestri I, Frati L, Aglianò AM. Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. Oncol Rep 14 (5):1199-202 (2005)

  • [8]Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358 (11):1160-74 (2008)

  • [9]Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 (2 Suppl):21-6 (2004)

  • [10]Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI: ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117 (8):2051-8 (2007)

  • [11]Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression asprognostic indicators in stage II colon cancer: a tissue microarray study.Clin Cancer Res 10 (9):3069-75 (2004)

  • [12]Galizia G, Lieto E, Ferraraccio F, De Vita F, Castellano P, Orditura M. Prognostic significance of epidermal growth factor receptor expression in coloncancer patients undergoing curative surgery. Ann Surg Oncol 13 (6):823-35 (2006)

  • [13]Chakrabarty S, Rajagopal S, Huang S: Expression of antisense epidermal growth factor receptor RNA down modulates the malignant behavior of human colon cancer cells. Clin Exp Metastasis 13 (3):191-5 (1995)

  • [14]Ravikumar TS, Wolf B, Cocchiaro C, D’Emilia J, Steele G Jr: Ras gene activation and epidermal growth factor receptor expression in human colon cancer. J Surg Res 47 (5):418-22 (1989)

  • [15]Darmoul D, Gratio V, Devaud H, Peiretti F, Laburthe M: Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol Cancer Res 2 (9):514-22 (2004)

  • [16]Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A 94 (2):657-62 (1997)

  • [17]Cheng K, Zimniak P, Raufman JP: Transactivation of the epidermal growth factor receptor mediates cholinergicagonist-induced proliferation of H508 human colon cancer cells. Cancer Res 63 (20):6744-50 (2003)

  • [18]Chen MC, Lee NH, Ho TJ, Hsu HH, Kuo CH, Kuo WW. Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells. Cancer Lett 349 (1):51-60 (2014)

  • [19]Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W. Epidermal growth factor receptor controls flat dysplastic aberrant crypt focidevelopment and colon cancer progression in the rat azoxymethane model.Clin Cancer Res 14 (8):2253-62 (2008)

  • [20]Xie G, Peng Z, Raufman JP: Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol 302 (9):G1006-15 (2012)

  • [21]Ongchin M, Sharratt E, Dominguez I, Simms N, Wang J, Cheney R. The effects of epidermal growth factor receptor activation and attenuation of the TGF beta pathway in an orthotopic model of colon cancer. J Surg Res 156 (2):250-6 (2009)

  • [22]Sasaki T, Nakamura T, Rebhun RB, Cheng H, Hale KS, Tsan RZ. Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in anorthotopic colon cancer model. Am J Pathol 173 (1):205-16 (2008)

  • [23]Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene 30 (29):3234-47 (2011)

  • [24]Sasaki T, Kitadai Y, Nakamura T, Kim JS, Tsan RZ, Kuwai T. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neoplasia 9 (12):1066-77 (2007)

  • [25]Chen A, Xu J, Johnson AC: Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25 (2):278-87 (2006)

  • [26]Ye YN, Liu ES, Shin VY, Wu WK, Luo JC, Cho CH: Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J Pharmacol Exp Ther 308 (1):66-72 (2004)

  • [27]Class Labeling Changes to anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix): KRAS Mutations. U.S. Food and Drug Administration. 2010-01-11.

  • [28]U.S. Food and Drug Administration

  • [29]Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (10):1626-34 (2008)

  • [30]Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (17):1757-65 (2008)

  • [31]Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29 (15):2011-9 (2011)

  • [32]Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25 (7):1346-55 (2014)

  • [33]Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, Braud F de. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–71 (2009)

  • [34]Geurs F, Vandewaeter S, Ponette S, Ponette J, Knape S, Demetter P: Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer. J Gastrointest Cancer 39 (1-4):26-8 (2008)

  • [35]Shitara K, Yokota T, Utsunomiya S: Cetuximab for patients with colon cancer and hepatic metastasis complicated by liver dysfunction and icterus. Gastrointest Cancer Res 3 (4):171-2 (2009)

  • [36]Tsuchida K, Hayashi S, Sawazaki S, Jin Y, Hasuo K, Suzuki H. A case of advanced colon cancer successfully treated with cetuximab diagnosed as EGFR-positive by liver biopsy. Gan To Kagaku Ryoho 38 (2):313-5 (2011)

  • [37]Toyama Y, Ushigome T, Watanabe K, Kitamura H, Onda S, Saito R. Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. World J Surg Oncol 10:129 (2012)

  • [38]Grigorean VT, Ciuhu AN, Rahnea Nita G, Strambu V, Straja DN, Popescu M. Efficacy of cetuximab in metastatic colon cancer - case report. Chirurgia (Bucur) 109 (3):383-9 (2014)

  • [39]Harada K, Hatanaka K, Kinoshita K, Kawamoto Y, Yamato H, Ogawa K. Successful treatment of advanced sigmoid colon cancer with liver metastases with cetuximab monotherapy as first-line treatment-a case report. Gan To Kagaku Ryoho 41 (7):897-900 (2014)

  • [40]Ojima E, Nakano T, Kanamoto A, Sasaki S: A case of advanced colon cancer successfully treated with combination therapy of cetuximab and oxaliplatin, leucovorin, and 5-fluorouracil. Gan To Kagaku Ryoho 40 (12):1962-4 (2013)

  • [41]Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T. Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRASp.G13D mutation. Oncol Lett 3 (2):269-272 (2012)

  • [42]Trojan J, Lubomierski N, Lehnert T, Engels K, Zeuzem S, Bechstein WO: Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. Z Gastroenterol 46 (8):776-9 (2008)

  • [43]Shibahara H, Kuze S, Kyokane T, Takamizawa J, Nakamura H, Morikawa S. A case of recurrent colon cancer with angina pectoris and interstitial pneumonia during cetuximab therapy with death by carcinomatous lymphangiosis. Gan To Kagaku Ryoho 37 (11):2193-8 (2010)

  • [44]Kawakami T, Okuyama Y, Enoki Y, Yoshida N: A case of recurrent lymph node metastases of advanced colon cancer with penetration of the gastric wall, treated effectively by cetuximab monotherapy as third-line treatment. Gan To Kagaku Ryoho 38 (11):1849-51 (2011)

  • [45]Zhang M, Tao W, Pan S, Sun X, Jiang H: Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs 20 (5):355-63 (2009)

  • [46]Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307 (13):1383-93 (2012)

  • [47]Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13 (2):100-9 (2014)

  • [48]Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 15 (8):862-73 (2014)

  • [49]Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS: The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. PLoS One 8 (3):e59380 (2013)

  • [50]Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27 (35):5924-30 (2009)

  • [51]Yamatodani T, Ekblad L, Kjellén E, Johnsson A, Mineta H, Wennerberg J: Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 135 (3):395-402 (2009)

  • [52]Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun 15 (2):91-100 (2009)

  • [53]Braud VM, Allan DS, O’Callaghan CA, Söderström K, D’Andrea A, Ogg GS. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (6669):795-9 (1998)

  • [54]Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 19 (24):6751-65 (2013)

  • [55]Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y. Cetuximab-induced MET activation acts as a novel resistance mechanism in coloncancer cells. Int J Mol Sci 15 (4):5838-51 (2014)

  • [56]Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. J Cancer Res Clin Oncol 140 (4):561-71 (2014)

  • [57]Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68 (6):1953-61 (2008)

  • [58]Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive tocetuximab. Mol Cancer 13:141 (2014)

  • [59]Yuan HH, Han Y, Bian WX, Liu L, Bai YX:The effect of monoclonal antibody cetuximab (C225) in combination with tyrosinekinase inhibitor gefitinib (ZD1839) on colon cancer cell lines. Pathology 44 (6):547-51 (2012)

  • [60]Luca T, Barresi V, Privitera G, Musso N, Caruso M, Condorelli DF, Castorina S: In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif 47 (5):435-47 (2014)

  • [61]Maya S, Sarmento B, Lakshmanan VK, Menon D, Jayakumar R:Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxelnanomedicines for epidermal growth factor receptor over expressing colon cancer cells. J Biomed Nanotechnol 10 (8):1416-28 (2014)

  • [62]Park MJ, Kim YS, Yang J, Sun WC, Park H, Chae SY. Pulsed high-intensity focused ultrasound therapy enhances targeted delivery of cetuximab to colon cancer xenograft model in mice. Ultrasound Med Biol 39 (2): 292-9 (2013)

  • [63]Solmi R, Lauriola M, Francesconi M, Martini D, Voltattorni M, Ceccarelli C.Displayed correlation between gene expression profiles and submicroscopicalterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer 8:227 (2008)

  • [64]Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini G. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer 130 (7):1577-89 (2012)

  • [65]Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP.Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression incolon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) Eur J Cancer 46 (9):1703-11 (2010)

  • [66]Lin WL, Lin WC, Yang JY, Chang YC, Ho HC, Yang LC. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 26 (16):2779-80 (2008)

  • [67]Uemoto J, Hamamoto Y, Onodera K, Nishi T, Warita E, Yamanaka Y. An autopsy case of unresectable colon cancer who developed lung injury by cetuximab. Gan To Kagaku Ryoho 40 (2):245-7 (2013)

  • [68]Plunkett, Jack W. Plunkett’s Biotech & Genetics Industry Almanac 2006. Plunkett Research. (September 30, 2005)

  • [69]Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS:Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther 14 (8): 703-10 (2013)

  • [70]Yoshida R, Matsuura T, Hijikawa K, Yanagida H, Kitade H, Takada H. A case of unresectable multiple hepatic metastases from ascending colon cancer successfully treated with panitumumab and FOLFIRI (5-FU/LV/irinotecan) therapy. Gan To Kagaku Ryoho 39 (10):1575-7 (2012)

  • [71]Nakatake R, Yamamichi K, Saito T, Ueda A, Tanaka H, Motohiro T, Kwon AH:Multiple hepatic metastases from colon cancer successfully treated with irinotecan and S-1 plus panitumumab as second-line therapy-a case report. Gan To Kagaku Ryoho 40 (12):2002-4 (2013)

  • [72]Horioka K, Kaku K, Jimi S, Oohata Y, Kamei T. A case of locally advanced sigmoid colon cancer curatively resected after neoadjuvant chemotherapy with FOLFIRI plus panitumumab. Gan To Kagaku Ryoho 40 (3):397-9 (2013)

  • [73]Honda K, Hata Y, Ihara E, Tomita Y, Miyata S, Sumida Y. A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens. Gan To Kagaku Ryoho 38 (9):1533-6 (2011)

  • [74]Yoshikawa K, Kuwata H, Nakahata Y. A case of curatively resected sigmoid colon cancer after mFOLFOX6 plus panitumumab neoadjuvant chemotherapy. Gan To Kagaku Ryoho 41(3):399-401 (2014)

  • [75]Leone F, Artale S, Marino D, Cagnazzo C, Cascinu S, Pinto C. Panitumumab in combination with infusionaloxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The Meta Pan study. Cancer 119 (19):3429-35 (2013)

  • [76]Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos HP: Autophagy: novel action of panitumumab in colon cancer. Anticancer Res 29(12):5077-82 (2009)

  • [77]GialeliCh, Theocharis AD, Kletsas D, Tzanakakis GN, Karamanos NK: Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab. Invest New Drugs 31(3):516-24 (2013)

  • [78]Toema BM. A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report. J Exp Ther Oncol 8 (4):321-5 (2010)

  • [79]Kornreich DA, Saif MW. Epistaxis secondary to panitumumab in a patient with colon cancer. Anticancer Res 32 (11):4983-5 (2012)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Review

Epidermal growth factor receptor-targeted therapy in colorectal cancer

WeiDong Xu 1,*, HuaYong Jing 1, FuLi Zhang 1
Affiliation
Article Info

1 Department of Radiation Oncology, The Military General Hospital of Beijing PLA, Beijing, 100700, China

Abstract

The epidermal growth factor receptor (EGFR) family plays an important role in colorectal cancer (CRC). EGFR participates in the key process of tumorigenesis and invasion, and its expression correlates with the prognosis of CRC. EGFR-targeted therapy has been widely utilized in stage III and IV CRC. The EGFR antibodies, cetuximab and panitumumab, are widely used in treatment of CRC. There are clinical trials and in vivo studies being carried out on the efficacy and mechanism of their action in CRC treatment. In this review, we will describe the EGFR-targeted therapy used in CRC, focusing on the efficacy and mechanisms of the most commonly used EGFR antibodies, cetuximab and panitumumab.

Keywords

  • Cetuximab
  • Panitumumab
  • Colorectal Cancer
  • Review

References